contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


enorama-pharma-ab-publ-explores-divestment-of-nicotine-replacement-therapy-chewing-gum-business

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Enorama Pharma is a pharmaceutical company. The company's operations are focused on producing and developing medical nicotine chewing gum. The products are sold mainly through retailers who sell the product under their own brand. The largest market is found in the Nordic region, but with a share of sales exported globally. Enorama Pharma was founded in 2006 and the headquarters are located in Malmö.

Enorama Pharma

The board of directors at Enorama Pharma AB ("Enorama Pharma" or the "Company") has decided to explore the possibility of divesting the part of the business developing and selling its nicotine...

<div class="abstract">The board of directors at Enorama Pharma AB ("Enorama Pharma" or the "Company") has decided to explore the possibility of divesting the part of the business developing and selling its nicotine replacement therapy ("NRT") chewing gum, to focus on the continued expansion of its NIC-S nicotine pouch product line.</div>Enorama Pharma has developed a patented range of NRT chewing gums in two strengths and two flavors, featuring superior gum characteristics. The product is already registered in seven European countries. Former CEO Annette Agerskov will lead the divestment process."I look forward to leading this process and believe the NRT business holds great value. We will carefully explore all options to ensure the best possible outcome for Enorama." says Annette Agerskov."It makes good sense for Enorama to evaluate a divestment of the NRT gum business. The NRT market is highly attractive to many international companies with established pharma operations. If the financial terms of the divestment are favorable, we plan to concentrate fully on expanding our pouch business, including markets outside the U.S." says Daniel Schröder, CEO of Enorama.CONTACTEnorama Pharma AB (publ)Daniel Schröder, VDinfo@enorama.seSödra Förstadsgatan 1, 211 43 Malmöwww.enorama.seEnorama Pharma AB is listed on Nasdaq First North Growth Market.The Company's Certified Adviser is Carnegie Investment Bank AB (publ): +46 (0)73 856 42 65, certifiedadviser@carnegie.se.ABOUT ENORAMA PHARMAEnorama Pharma's goal is to become a leading global supplier of consumer-friendly nicotine replacement products. The business concept is to develop and sell both medical chewing gum and non-medical, tobacco-free nicotine products and offer these both as Private Label and under own brands. For more information, visit www.enorama.se.This information is information that Enorama Pharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-09-25 12:00 CEST.

Enorama Pharma AB (publ) Explores Divestment of Nicotine Replacement Therapy Chewing Gum Business